* DUPIXENT ® is the only biologic medicine approved by Health Canada to treat moderate-to-severe atopic dermatitis. * Public reimbursement under the Ontario Exceptional Access Program and the New ...
Single-dose (300 mg) pre-filled pen provides additional administration option to adults and adolescents who are prescribed Dupixent 300 mg pre-filled pen expected to be available third quarter of 2020 ...
The FINANCIAL — Sanofi and Regeneron Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) Injection, the first and only biologic ...
TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...
Dupixent is approved in 60 countries for adults with moderate-to-severe atopic dermatitis, one of the diseases driven by type 2 inflammation Atopic dermatitis is a chronic inflammatory disease that ...
Rivals are closing in on Sanofi and Regeneron’s Dupixent. With AbbVie’s Rinvoq having already bested Dupixent in atopic dermatitis, Pfizer has now chalked up its own efficacy win over the blockbuster ...
Dupixent is a prescription medication that can help manage chronic inflammatory conditions in children, such as eczema, asthma, and eosinophilic esophagitis. It can be exhausting for a child to ...
July 3 (Reuters) - Sanofi (SASY.PA), opens new tab and partner Regeneron (REGN.O), opens new tab on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Sanofi logo at the company's headquarters during the annual results news conference in Paris (Reuters) -Sanofi won ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results